
James Hohmann @jameshohmann
The Federal Trade Commission on Tuesday announced plans to reconsider its approach to scrutinizing pharmaceutical mergers, with an eye toward taking a more aggressive stance against drug-company deals that may harm competition. https://t.co/kW0w2wi7dX — PolitiTweet.org